CELLphenomics and Charles River Laboratories International, Inc. (NYSE: CRL) announced an agreement, that provides Charles River clients with access to CELLphenomics’ proprietary 3D tumor model platform, PD3D®, which will expand Charles River’s 3D in vitro testing services to further optimize oncological approaches for its clients. CELLphenomics’ core competence is the establishment and cultivation of complex […]
continue readingKYAN Technologies, Alentis Therapeutics, and CELLphenomics Join Forces Combining Cutting-edge Optim.AI™ and PD3D® Models to Advance Claudin-1 Expression Research
KYAN Technologies, a vanguard combinatory drug development solutions provider, is thrilled to announce a strategic partnership with Alentis Therapeutics, a clinical-stage biopharmaceutical company developing breakthrough treatments for Claudin-1 positive tumours and organ fibrosis. This partnership aims to accelerate research into Claudin-1 expression using innovative patientderived 3D (PD3D®) cell culture models provided by CELLphenomics. Claudin-1 (CLDN1) […]
continue readingBerlin scientists use tumor samples drawn from patients with soft tissue sarcomas to individually test their tumor response to ionizing radiation and lay one stepstone towards a translational platform for personalized radiation oncology for rare malignant
Soft tissue sarcomas are a rare group of malignant tumors arising from connective tissue cells, of which more than 70 different subtypes are known to date. The standard therapy for localized, high-grade soft tissue sarcomas is surgery and pre- or postoperative radiation. Despite the known multitude of subtypes, according to US-American and European guidelines all […]
continue readingBowel cancer: Researchers find possible cause for chemoresistance and partially used patient-derived 3D cell culture models for their studies.
Large quantities of the protein IGF2BP2 not only make bowel cancer grow faster, but they also make it resistant to common forms of chemotherapy. This discovery was made by a research team led by Martin Luther University Halle-Wittenberg (MLU) and Saarland University with the collaboration of CELLphenomics. For its new study, published in the scientific […]
continue readingCELLphenomics’ and KYAN Therapeutics combined platforms provide best-in-class solutions to support the biopharma industry
CELLphenomics and KYAN Therapeutics announced their new partnership today. By combining KYAN’s technology platform, Optim.AI™ – which utilizes artificial intelligence to predict the effects of drug combinations and CELLphenomics‘ proprietary PD3D® technology, this partnership aims to offer an efficient approach to expedite drug development process in the biopharmaceutical industry. The combination of these two unique […]
continue readingEuropean Union-Funded Project to Result in Novel Treatment Approaches for Several Solid Tumor Types
Indivumed GmbH (“Indivumed”) and CELLphenomics GmbH (“CELLphenomics”) today announced a partnership to create a unique platform for faster and more efficient discovery and validation of therapeutic targets. The new platform combines Indivumed’s AI-driven oncology analytics with CELLphenomics’ expertise in creating organoid models to identify therapeutically relevant targets and validate these targets in-vitro. The partnership will […]
continue readingVon der Europäischen Union finanziertes Projekt soll zu neuen Therapieansätzen verschiedener solider Tumorarten führen
Indivumed GmbH („Indivumed“) und CELLphenomics GmbH („CELLphenomics“) geben heute ihre Partnerschaft bekannt, in der eine bisher einzigartige Plattform entsteht, die eine schnellere und effizientere Identifizierung und Validierung therapeutischer Targets ermöglichen wird. Die neue Plattform kombiniert die KI-gestützten onkologischen Analysemethoden von Indivumed mit der Expertise von CELLphenomics im Bereich der Entwicklung von Organoid-Modellen, um therapeutisch relevante […]
continue reading